{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ANAB",
  "name": "AnaptysBio, Inc.",
  "url": "https://orbyd.app/dossiers/ANAB/",
  "json_url": "https://orbyd.app/dossiers/ANAB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The July 14–17 Delaware bench trial closed with no verdict and no buyout; the quick-resolution crowd unwound and ANAB round-tripped from the low-$70s to ~$54 (Jul 24). The whole equity is now a dateless wait on a Chancery post-trial opinion deciding Jemperli royalty reversion — a low-beta binary with no tape and the timer removed.",
  "invalidation_trigger": "A weekly close below $48 breaks the post-spin base that has held since the April 20 spin-off and signals the market pricing an adverse ruling; separately, a Chancery post-trial opinion denying Jemperli reversion and reopening Tesaro's royalty-cut path is the fundamental thesis-break regardless of price.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Beta 0.41 — trades on legal/royalty headlines, not tape. Rosnilimab UC Phase 2 failed 2025-11-10 and RA Phase 2b was positive, but both now belong to TRAX, not ANAB.",
    "Spot ~$50 (last ref $50.37, 2026-06-05) pins the floor of the $50–140 analyst band; ~$40 is the unfilled April court-ruling gap and the post-spin base break level. $73.30 is the round-tripped 52-week high.",
    "Binary event already occurred: the Delaware Chancery bench trial ran 2026-07-14 to 2026-07-17 and closed with NO verdict and NO buyout. The live catalyst is now the DATELESS post-trial written opinion, not the trial date — do not re-set a July catalyst_date.",
    "Chancery post-trial opinions can land weeks to months after closing arguments — treat timing as open-ended; expect a ±20–40% gap on the ruling given beta ~0.41 and single-asset dependence.",
    "Post-April-spin structure is permanent: ANAB is a pure-play royalty book (Jemperli/GSK + imsidolimab/Vanda). Clinical pipeline (rosnilimab, ANB033, ANB101) + cash went to First Tracks (Nasdaq: TRAX), spin completed 2026-04-20. Do NOT credit ANAB with pipeline optionality or the old SGMT/biotech-precision momentum peer framing.",
    "Balance sheet: ~$140–145M net cash post-spin; Jemperli royalty tiered 8–25% (25% above $2.5B net sales), peak sales projected >$2.7B, ~$390M annualized royalty value contested in the litigation.",
    "Second royalty trigger: imsidolimab (Vanda) FDA action date 2026-12-12 for generalized pustular psoriasis; Phase III published in NEJM ~2026-04-29. Beyond the 30-day window but the next dated event after the opinion.",
    "Not a momentum vehicle: round-tripped $73.30 52-week high to ~$54 (Jul 24, 2026) via two July gap-downs (to $55.76 ~Jul 14, then ~-13% Jul 20). Fresh momentum-book entries require a resolved opinion or a fresh base+catalyst, not the current dateless limbo."
  ],
  "body_markdown": "## Current Thesis\nThe binary this whole equity was built around has already happened, and it produced nothing to trade. The Delaware Chancery bench trial in the Tesaro/GSK dispute ran July 14–17, 2026 and closed with no verdict and no buyout headline. The crowd that had positioned for a clean win or a quick GSK take-out unwound into the close: ANAB slid roughly 11% into the trial week (to $55.76 around July 14) and dropped a further ~13% on July 20, finishing at $54.15 on July 24 — a full round-trip of the post-spin advance that had carried it to the $73.30 52-week high. What remains is a pure-play royalty stub (Jemperli/GSK, imsidolimab/Vanda) whose fate now sits with a Vice Chancellor's post-trial written opinion deciding whether Jemperli royalty rights revert to Anaptys or Tesaro's royalty-cut path reopens. That opinion has no public date and can land weeks to months after closing arguments. This is a low-beta coin-flip with the timer removed — no accelerating tape, no cluster, nothing a narrative-momentum book is built to catch.\n\n## Bull Case\n- **Royalty annuity on a growing PD-1.** Jemperli (dostarlimab) pays a tiered 8–25% royalty, reaching 25% above $2.5B net sales, with peak sales projected north of $2.7B and composition-of-matter coverage into the mid-2030s — a non-dilutive recurring stream on a GSK oncology franchise still adding indications. Roughly $390M of annualized royalty value is what the litigation contests.\n- **Legal momentum from April.** The April 24, 2026 pre-trial ruling dismissed Tesaro's anticipatory-breach claim and rejected its royalty-reduction request, popping the stock ~12% on April 27; Anaptys's own reversion claims survived into the July trial. A favorable written opinion could recapture full Jemperli economics, not merely preserve the rate.\n- **Clean post-spin balance sheet.** The First Tracks (Nasdaq: TRAX) spin completed April 20, 2026 offloaded the clinical pipeline and cash burn; ANAB carries ~$140–145M net cash with no R&D drain — a royalty book plus a legal option.\n- **Sell-side still constructive.** Consensus Buy with an average target near $75 versus $54.15 spot (~+39%), a range from UBS $60 (Apr 21) to Piper $93 (May 4) and HC Wainwright $95 (Jun 10), and no published sells.\n- **Second dated royalty trigger.** Imsidolimab (Vanda) carries an FDA action date of December 12, 2026 for generalized pustular psoriasis, with Phase III data in NEJM (~Apr 29, 2026); approval adds a stream at no incremental ANAB cost.\n\n## Bear Case\n- **The catalyst fired and delivered nothing.** The July 14–17 trial ended with no ruling and no deal; the two July gap-downs (to $55.76 mid-month, then ~-13% on July 20) are the market unwinding the clean-win-or-buyout bet in real time.\n- **The timer is gone.** A Chancery post-trial opinion routinely arrives weeks to months after closing arguments. The equity can drift with no catalyst and no momentum for an indeterminate stretch — dead money with a binary tail.\n- **Court outcomes aren't modellable.** An adverse opinion vaporizes the reversion option and reopens Tesaro's royalty-cut path; there is no analytical edge in handicapping a bench ruling.\n- **Single-counterparty dependence.** Value rides entirely on GSK's execution of Jemperli — any deprioritization or label setback hits the annuity, and the pipeline that could have offset it left with TRAX on April 20.\n- **Broken price structure.** Down from the $73.30 high to $54, below where it traded pre-trial, with beta ~0.41 — it moves on legal headlines, not the tape, so there is no trend for a momentum vehicle to lean on.\n\n## Setup & Price Structure\n- Spot $54.15 (Jul 24, 2026); 52-week range $17.11–$73.30. The name has surrendered its entire post-spin advance — the April 27 ruling pop and the run to $73.30 have fully reversed.\n- Two distinct July down legs: ~-11% into the trial week (to $55.76 around July 14) and ~-13% on July 20 as quick-resolution longs exited. Price is now consolidating in the low-$50s.\n- The post-spin base built since the April 20 completion sits near $50; the April court-ruling gap fills into the mid-$40s beneath it. There is no momentum shelf to buy against.\n- For a narrative-velocity entry there is nothing here: no accelerating tape, no peer cluster, a dateless binary. The disciplined read is to stand aside until either the opinion prints or a fresh base plus catalyst forms.\n\n## Catalyst Calendar (next 30 days)\n- **Delaware Chancery post-trial written opinion — no fixed date.** Trial closed July 17, 2026; the opinion can arrive weeks to months out. This is the dominant driver — expect a violent ±20–40% gap whenever it lands.\n- **Q2 2026 results — est. ~early-to-mid August 2026** (10-Q for the quarter ended June 30; exact date unconfirmed). A royalty run-rate and cash update; second-order for a legal-binary name.\n- **Imsidolimab (Vanda) FDA action date — 2026-12-12** (beyond the 30-day window; flagged as the next dated event after the opinion).\n\n## What Would Change Our Mind\nA favorable written opinion granting Jemperli reversion re-rates the equity toward the $95–140 upside band and converts the stub into a full-economics royalty book — that is the accelerant that would make this tradeable on strength rather than on hope. On the downside, a weekly close below $48 breaks the post-spin base and signals the market pricing an adverse ruling, with the April gap toward the mid-$40s opening beneath. A GSK settlement or buyout headline collapses the range either way inside 24 hours. Confirmation that the opinion is slipping into Q4 simply extends the dead-money limbo and lowers any reason to carry exposure through it.\n\n## Correlation Notes\n- Idiosyncratic and low-beta (~0.41): the name drives on legal and royalty headlines, not the broad tape or biotech beta (XBI/IBB). It is a poor hedge and a poor momentum vehicle.\n- Loosely linked to GSK as partner/counterparty and to First Tracks (TRAX) as the sibling equity holding the old pipeline, but the two have traded on separate stories since the April 20 spin completed.\n- The closer cohort is event-driven royalty and litigation special-situations (e.g. XOMA Royalty), not precision-biotech momentum — the old SGMT/biotech-precision peer framing left with the spin and should not be reintroduced.",
  "first_seen": "2026-04-28",
  "last_analyzed": "2026-07-26T11:43:04+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}